search icon

    Market Snapshot

    • S&P Futures

      3,814.5

    • Dow Futures

      30,961

    • Nasdaq Futures

      11,557.75

    blog search icon

    Clovis Oncology, Inc.

    (NASDAQ:CLVS)

    $2.85

    $1.05

    58.33%

    Clovis Oncology, Inc. Chart

    CLVS Stock Price Today

    Clovis Oncology, Inc. (CLVS) stock rallied over 58.33% intraday to trade at $2.85 a share on NASDAQ. The stock opened with a gain of 69.64% at $1.78 and touched an intraday high of $2.9, rising 58.33% against the last close of $1.8. The stock went to a low of $1.78 during the session.

    Stock Snapshot

    $1.8

    Prev. Close

    259.01 Million

    Market Cap

    $1.78

    Day Low

    $1.78

    Open

    138.21 Million

    Number of Shares

    $2.9

    Day High

    -

    P/E ratio

    -2.11

    EPS (TTM)

    1.01

    Cash Flow per Share

    -

    Free Float in %

    -1.76

    Book Value

    75,260,446

    Volume

    Clovis Oncology, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-01$1.78$2.9$1.78$2.8575,854,400
    2022-06-30$1.68$1.95$1.63$1.812,547,200
    2022-06-29$1.69$1.71$1.55$1.714,219,000
    2022-06-28$1.7$1.85$1.62$1.717,424,400
    2022-06-27$1.81$1.81$1.57$1.718,371,300
    2022-06-24$1.66$1.91$1.66$1.727,276,300
    2022-06-23$1.4$1.77$1.34$1.7419,407,200
    2022-06-22$1.74$1.84$1.47$1.5330,790,500
    2022-06-21$1.3$2.4$1.28$1.64110,210,100
    2022-06-17$0.89$1.2$0.88$1.1819,364,100

    Contact Details

    5500 Flatiron Parkway
    Suite 100
    Boulder, CO 80301
    United States

    Webiste:CLVS

    303 625 5000

    Company Information

    Employees-

    Beta0.49

    Sales or Revenue148.76 Million

    5Y Sales Change353.00%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.

    Frequently Asked Questions

    icon

    What is the current Clovis Oncology, Inc. (CLVS) stock price?

    Clovis Oncology, Inc. (NASDAQ: CLVS) stock price is $2.85 as of the last check on Friday, July 1. During the trading session, CLVS stock reached the peak price of $2.9 while $1.78 was the lowest point it dropped to.

    icon

    CLVS's industry and sector of operation?

    The NASDAQ listed CLVS is part of Biotechnology industry that operates in the broader Health Care sector. Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

    icon

    Who are the executives of CLVS?

    Dr. Gillian C. Ivers-Read
    Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations
    Mr. Patrick J. Mahaffy MA
    Co-Founder, CEO, Pres & Exec. Director
    Dr. Gillian C. Ivers-Read BSc
    Co-Founder, Exec. VP & Chief Regulatory Officer
    Mr. Daniel W. Muehl
    Exec. VP & CFO

    icon

    What is the CLVS stock price today?

    CLVS stock traded closed the last session at $2.85, which is $1.05 or 58.33% lower than its previous close of $1.8. CLVS's current trading price is 390.53% lower than its 52-week high of $5.92 where as its distance from 52-week low of 0.58% is -51.86%.

    icon

    How many employees does CLVS have?

    Number of CLVS employees currently stands at -. CLVS operates from 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301, United States.

    icon

    Link for CLVS official website?

    Official Webiste of $CLVS is: https://www.clovisoncology.com

    icon

    How do I contact CLVS?

    CLVS could be contacted at CLVS operates from 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301, United States, or at phone #303 625 5000 and can also be accessed through its website.

    icon

    How many shares of CLVS are traded daily?

    CLVS stock volume for the day was 75,260,446 shares while in the previous session number of CLVS shares traded was 75,854,400 . The average number of CLVS shares traded daily for last 3 months was 16.2 Million.

    icon

    How much did CLVS change today?

    The percentage change in CLVS stock occurred in the recent session was 58.33% while the dollar amount for the price change in CLVS stock was $1.05.

    icon

    What price range CLVS stock been trading in?

    In the recent session, the day high for CLVS stock was $2.9 while the low for CLVS stock touched on the day was $1.78.

    icon

    What is the market cap of CLVS currently?

    The market value of CLVS currently stands at 259.01 Million with its latest stock price at $2.85 and 138.21 Million of its shares outstanding.